Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
0 patents granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Actinium Pharmaceuticals, Inc’s names, not what it holds today.
Patents granted
0
by type: not read, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
53
7 of them in 2025
Names they are printed under
1
its own name
By yearGrantedApplications published
'13'17'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name1 counted
ACTINIUM PHARMACEUTICALS, INC. its own name
named as the applicant on its applications, in US
53 published
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Nov 6, 2025 | 2025/0339571 | RADIOIMMUNOCONJUGATES TARGETING PHOSPHATIDYLSERINE FOR USE IN THE TREATMENT OF CANCER | Pharmaceuticals | ACTINIUM PHARMACEUTICALS, INC. |
| Sep 18, 2025 | 2025/0289875 | GRP78 NANOBODIES | Pharmaceuticals | ACTINIUM PHARMACEUTICALS, INC. |
| Sep 11, 2025 | 2025/0281654 | METHODS FOR TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS | Pharmaceuticals | ACTINIUM PHARMACEUTICALS, INC. |
| Jun 26, 2025 | 2025/0205375 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | Pharmaceuticals | ACTINIUM PHARMACEUTICALS, INC. |
| Apr 17, 2025 | 2025/0121105 | METHODS FOR TREATING CANCER USING COMBINATIONS OF PARP INHIBITORS AND ANTIBODY RADIOCONJUGATES | Pharmaceuticals | ACTINIUM PHARMACEUTICALS, INC. |
| Mar 6, 2025 | 2025/0073274 | METHODS FOR TREATING CD33-POSITIVE HEMATOLOGICAL MALIGNANCIES | Pharmaceuticals | ACTINIUM PHARMACEUTICALS, INC. |
| Jan 16, 2025 | 2025/0017919 | METHOD FOR TREATING CANCER USING A BCL-2 INHIBITOR IN CONJUNCTION WITH AN ALPHA-EMITTING RADIOIMMUNOTHERAPEUTIC | Pharmaceuticals | ACTINIUM PHARMACEUTICALS, INC. |
| Dec 12, 2024 | 2024/0408250 | METHODS FOR TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES | Pharmaceuticals | ACTINIUM PHARMACEUTICALS, INC. |
| Nov 28, 2024 | 2024/0390532 | RADIOIMMUNOCONJUGATES TARGETING GRP78 FOR USE IN THE TREATMENT OF CANCER | Pharmaceuticals | ACTINIUM PHARMACEUTICALS, INC. |
| Sep 12, 2024 | 2024/0301081 | HUMANIZED ANTI-CD45 ANTIBODIES | Pharmaceuticals | ACTINIUM PHARMACEUTICALS, INC. |
What it applied for, 2024 to 2025: Pharmaceuticals 18 · Organic fine chemistry 3.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.